Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience

Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor, which is United States Food and Drug Administration (FDA)-approved for chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia. Ibrutinib is associated with atrial fibrillation and bleeding events. Our aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalid, Sidra, Yasar, Samin, Khalid, Aariez, Spiro, Timothy PP, Haddad, Abdo, Daw, Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063389/
https://www.ncbi.nlm.nih.gov/pubmed/30062075
http://dx.doi.org/10.7759/cureus.2701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063389/
https://www.ncbi.nlm.nih.gov/pubmed/30062075
http://dx.doi.org/10.7759/cureus.2701

Ejemplares similares